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ABSTRACT
This study reviewed 56 patients with signiﬁcant
metallo-b-lactamase (MBL)-producing Pseudo-
monas aeruginosa infections between May 2002
and March 2004 to identify features associated
with mortality. Immunosuppression (p 0.002),
bacteraemia (p 0.08) and inadequate antimicro-
bial therapy (p <0.001) were associated with
death. Among those patients treated with ade-
quate therapy, the use of multiple drug treatment
regimens (two or three active agents) was associ-
ated with a non-signiﬁcant two-fold increase in
survival (p 0.45). Further prospective studies are
warranted to determine the optimal treatment of
MBL-producing P. aeruginosa infections.
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Metallo-b-lactamases (MBLs) comprise a group of
b-lactamases that are highly active hydrolysers of
carbapenems, and have potent but variable enzy-
mic activity against other b-lactam antibiotics,
except the monobactams [1,2]. MBLs are not
usually susceptible to conventional b-lactamase
inhibitors. Furthermore, genes encoding MBLs are
commonly found in cassettes associated with
multidrug resistance integrons [3,4]. MBL-produ-
cing Pseudomonas aeruginosa strains are of partic-
ular importance, given their potential for
horizontal spread and the relatively small number
of potential therapeutic agents [5,6]. However,
there remains a relative paucity of information
regarding the optimal treatment regimens for
infections caused byMBL-producingP. aeruginosa.
This report describes a retrospective case series
review of the treatment of MBL-producing
P. aeruginosa infections in three major adult
acute-care facilities.
All adult patients (aged ‡18 years) in the
Calgary Health Region (catchment area c. 1.5 mil-
lion individuals) with a positive clinical culture
for MBL-producing P. aeruginosa between May
2002 and March 2004 were identiﬁed using a
centralised laboratory database, as described pre-
viously [7,8]. Isolates were tested for antimicro-
bial susceptibility using standard techniques [9],
and MBLs were identiﬁed using PCRs with VIM-,
IMP-, GIM- and SPM-speciﬁc primers [7,8,10,11].
The study was limited to clinically signiﬁcant
infections deﬁned by (i) a positive sterile-site
culture, or (ii) a positive non-sterile-site clinical
isolate associated with symptoms and signs of
infection, and either ﬁve or more consecutive
days of anti-pseudomonal therapy or death dur-
ing the course of infection. Infection was deﬁned
as community-acquired if the organism was
isolated within 48 h of hospitalisation. Adequate
treatment was deﬁned as use of an antibacterial
agent to which the organism was fully susceptible
within 48 h of collecting the culture for a partic-
ular infection episode. Mortality was deﬁned as
all causes of death during hospitalisation.
In total, 56 patients with signiﬁcant MBL-
producing P. aeruginosa infections were identiﬁed
during the study period. The mean age of the
patients was 63 ± 16 years. Fifty (89%) cases were
nosocomially acquired, with a median time-to-
acquisition of 19 days (inter-quartile range
(IQR) 7–36 days). Sites of infection were pulmon-
ary in 23 (41%) cases, urinary in 17 (30%) cases,
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bloodstream associated with fevers in neutropenic
patients in ten (18%) cases, soft-tissue in four
(7%) cases, central line in one (2%) case, and
peritoneal in one (2%) case. There was no associ-
ation between the site of infection and increased
mortality.
Of the MBL-producing isolates recovered, 53
(93%) produced VIM-2, one (2%) produced IMP-
7, and MBLs were not identiﬁed for two (4%)
(i.e., these isolates were phenotypically positive
for MBL production, but were negative in VIM-,
IMP-, GIM- and SPM-speciﬁc PCRs). Among the
MBL-producing P. aeruginosa clinical isolates tes-
ted, 98% were insusceptible to either tobramycin
or amikacin, 93% to ciproﬂoxacin, 93% to ceftaz-
idime, 93% to gentamicin, 21% to piperacillin,
11% to aztreonam, and 10% to colistin. The
addition of tazobactam to piperacillin reduced
rates of insusceptibility from 21% to 5%.
Patients were treated with a variety of regi-
mens at the discretion of the attending physi-
cians (Fig. 1). Forty-eight patients were treated
with piperacillin–tazobactam for a median of
11 days (IQR 7.5–16 days). Eight patients were
treated with aztreonam for a median of 11 days
(IQR 8–12.5 days). Two patients were treated
with intravenous colistin and seven with nebu-
lised colistin for a median of 14 days
(IQR 10–20 days).
The overall case fatality rate associated with
MBL-producing P. aeruginosa infection was 29%
(16 ⁄ 56). Important predictors of death were inad-
equate treatment, host immunosuppression and
bacteraemia, as shown in Table 1. Neither cancer,
diabetes, chronic cardio-respiratory, renal nor
liver disease were associated signiﬁcantly with
mortality (p >0.1). Among the subgroup of
patients treated adequately (n = 48), a non-signi-
ﬁcant doubling of survival rates was observed
following the use of multiple drug regimens (7 ⁄ 30
(23%) vs. 2 ⁄ 18 (11%), p 0.45).
A particularly important observation in this
study was the absence of piperacillin or pipera-
cillin–tazobactam resistance among the MBL-pro-
ducing isolates (21% and 5%, respectively).
Accordingly, piperacillin–tazobactam was the
backbone of most of the treatment regimens, but
was still associated with frequent treatment fail-
ure. Aztreonam has been used commonly at our
institutions as a second b-lactam agent, despite
animal data showing questionable efﬁcacy [12],
and clinical outcomes have been comparable
to those obtained with other agents. Colistin
was well-tolerated, and no colistin-associated
56 patients with clinically
relevant infections
39 patients
survived
1 patient
survived
9 patients
died
7 patients
died
8 treated
inadequately
48 treated
adequately
22 TZP alone
7 TZP + COL
7 TZP
1 TZP + COL + ATM
1 TZP + COL + GEN
1 FEP + GEN
1 TZP + CIP
1 CIP
1 TZP + CAZ
2 CAZ + CIP
1 TZP + CIP
1 TOB + MEM + IPM
1 TOB + MEM
1 CAZ
1 GEN
1 ATM
6 TZP + ATM
Fig. 1. Treatment regimens of patients infected with metallo-b-lactamase-producing Pseudomonas aeruginosa. TZP,
piperacillin–tazobactam; COL, colistin; ATM, aztreonam; FEP, ceﬁpime; GEN, gentamicin; CIP, ciproﬂoxacin; CAZ,
ceftazadime; TOB, tobramycin; MEM, meropenem; IPM, imipenem.
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neurological or nephrotoxicity was observed,
which is consistent with other studies showing
low toxicity proﬁles [13–16].
The use of combination therapy for P. aerugi-
nosa infections is being debated in the literature
[17–20]. Advocates of combination therapy
emphasise the high mortality rate associated with
P. aeruginosa infections, and the high rates of
intrinsic resistance. The present study showed a
two-fold increase in patient survival with ade-
quate combination therapy. However, this
increase did not reach signiﬁcance, probably
because of the small study cohort.
Given the retrospective observational basis of
this study, a number of biases are inherent.
Furthermore, factors such as concurrent secon-
dary infection, allergies and contra-indications to
treatment agents were not assessed speciﬁcally
and would affect the treatment regimens pre-
scribed. Given the tremendous variation in the
substrate speciﬁcities of MBLs, the results may be
generalisable only to the VIM-2 strain that is
endemic in the Calgary region. Within these
recognised limitations, several important obser-
vations were made regarding the initiation of
appropriate antimicrobial agents. The high mor-
tality rates associated with inadequate initial
treatment regimens underscore the importance
of screening populations at particular risk for
MBL-producing P. aeruginosa strains (i.e., inten-
sive care unit, oncology and immunosuppressed
patients) and the need for knowledge of local
antibiograms for selection of appropriate empir-
ical treatments. Furthermore, the global dissem-
ination of the genes encoding MBLs places further
emphasis on the importance of national and
multinational resistance surveillance consortia to
track the spread of MBL-producing organisms [1].
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ABSTRACT
The in-vivo activity of imipenem against VIM-1-
producing Klebsiella pneumoniae (VPKP) was as-
sessed in a thigh infection model in neutropenic
mice. Animals were infected with three VPKP
isolates (imipenem MICs 2, 4 and 32 mg ⁄L,
respectively) and a susceptible clinical isolate
(MIC 0.125 mg ⁄L) that did not produce any b-
lactamase with broad-spectrum activity. Bacterial
density at the site of infection was determined
after imipenem treatment (30 and 60 mg ⁄ kg every
2 h for 24 h). The log10 reduction in CFU ⁄ thigh
was greatest for the wild-type isolate, intermedi-
ate for the two imipenem-susceptible VPKP iso-
lates, and lowest for the imipenem-resistant
VPKP isolate. Whilst in-vivo imipenem activity
appeared reduced against in-vitro susceptible
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